University College London Hospitals NHS Foundation Trust, University College Hospital London
Welcome,         Profile    Billing    Logout  
 4 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bridgewater, John A
SAFIR-ABC10, NCT05615818: Personalized Medicine for Advanced Biliary Cancer Patients

Recruiting
3
800
Europe
Futibatinib, Ivosidenib, Tibsovo, Zanidatamab, Trastuzumab, Zercepac, Neratinib, Nerlynx, Encorafenib, Braftovi, Binimetinib, Mektovi, Niraparib, Zejula, Cisplatin, Gemcitabine
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, National Cancer Institute, France, Cancer Research UK, Taiho Oncology, Inc., Servier, Zymeworks BC Inc., Accord Healthcare, Inc., Pierre Fabre Medicament
Biliary Tract Neoplasms
06/27
06/28
SEVILLA, NCT06529718: Testing Ivonescimab Versus FOLFOX in Advanced Biliary Tract Cancer Patients

Not yet recruiting
2
72
Europe
Ivonescimab, FOLFOX regimen
UNICANCER, Cancer Research UK & UCL Cancer Trials Centre, Belgian Group of Digestive Oncology, Summit Therapeutics
Biliary Tract Cancer
08/27
01/29
DECIPHER, NCT05965479: Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Recruiting
2
25
Europe
Trastuzumab deruxtecan, Enhertu
University of Southampton, AstraZeneca, Natera, Inc.
Gastrooesophageal Cancer
03/26
04/28
TRacKING, NCT04921553: Real Word European Registry of NTRK Fusions and Other Rare Actionable Fusions

Recruiting
N/A
500
Europe, RoW
Data collection and quality of life questionnaire
Centre Leon Berard
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression, NTRK Family Gene Mutation, ATIC-ALK Fusion Protein Expression, ALK Fusion Protein Expression, BCR-FGFR1 Fusion Protein Expression, ROS1 Gene Translocation, COL1A1-PDGFB Fusion Protein Expression, RET Gene Translocation, Gene Fusion, ROS Gene Translocation, BRAF Gene Rearrangement, FGFR2 Gene Translocation, FGFR3 Gene Translocation, NTRK1 Gene Translocation
06/25
06/25
Ford, Hugo
DECIPHER, NCT05965479: Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Recruiting
2
25
Europe
Trastuzumab deruxtecan, Enhertu
University of Southampton, AstraZeneca, Natera, Inc.
Gastrooesophageal Cancer
03/26
04/28
O'Neill, Robert
DECIPHER, NCT05965479: Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Recruiting
2
25
Europe
Trastuzumab deruxtecan, Enhertu
University of Southampton, AstraZeneca, Natera, Inc.
Gastrooesophageal Cancer
03/26
04/28
Davies, Jessica
DECIPHER, NCT05965479: Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer

Recruiting
2
25
Europe
Trastuzumab deruxtecan, Enhertu
University of Southampton, AstraZeneca, Natera, Inc.
Gastrooesophageal Cancer
03/26
04/28

Download Options